SCHEMBL30121029

SCHEMBL30121029

Cc1cnc(Cc2cc(F)cc(C(F)(F)F)c2)cc1-n1cc(C(=O)O)c(C)n1

nearest known ligand 0.44

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
GPR52 Q9Y2T5 17/20 0.44
ALKBH1 Q13686 1/20 0.37
RORC P51449 1/20 0.37
CMA1 P23946 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23824115 1.00 GPR52 (0.44) GPR52ALKBH1RORCCMA1
SCHEMBL23803831 0.91 GPR52 (0.52) GPR52
SCHEMBL30120785 0.91 GPR52 (0.52) GPR52
SCHEMBL30120818 0.89 GPR52 (0.42) GPR52
SCHEMBL23803908 0.89 GPR52 (0.42) GPR52
SCHEMBL30152262 0.89 GPR52 (0.42) GPR52
SCHEMBL23803849 0.83 GPR52 (0.57) GPR52RORCCMA1
SCHEMBL30120969 0.83 GPR52 (0.57) GPR52RORCCMA1
SCHEMBL23803837 0.74 GPR52 (0.56) GPR52
SCHEMBL30152179 0.74 GPR52 (0.56) GPR52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4117784-B1 GPR52 MODULATOR COMPOUNDS NXERA PHARMA UK LTD (GB) 2024-08-28 EP disclosed
US-20240254101-A1 GPR52 MODULATOR COMPOUNDS HEPTARES THERAPEUTICS LIMITED (GB) 2024-08-01 US disclosed
EP-4117784-A1 GPR52 MODULATOR COMPOUNDS Heptares Therapeutics Limited (GB) 2023-01-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240254101-A1 GPR52 MODULATOR COMPOUNDS GPR52, GPR119, GPR4 GPR52 1/4885ALKBH1 4623/4885RORC 384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.